Dr. Jack Hoppin, CEO & Dr. John Babich, CSO - Ratio Therapeutics - Best-In-Class Targeted Radiotherapeutics For Cancer

Progress, Potential, and Possibilities

Send us a text

Dr. Jack Hoppin, Ph.D. is Chairman and Chief Executive Officer of Ratio Therapeutics ( https://ratiotx.com/ ), a discovery through early clinical phase pharmaceutical company, employing a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers. Dr. Hoppin holds a Ph.D. in Applied Mathematics from the University of Arizona and worked as an Alexander von Humboldt post-doctoral fellow at the Research Center Jülich, Germany. Previously, Dr. Hoppin was the President of Konica Minolta Precision Medicine, Co-Founder and CEO of Invicro, VP of Imaging Systems at Bioscan, Inc. and has a couple decades of experience in imaging research. As an active member of the imaging community, Dr. Hoppin is a member of the World Molecular Imaging Society Board of Trustees. Dr. John Babich, Ph.D. is Director, President, and Chief Scientific Officer of Ratio Therapeutics and has been an active researcher in the field of molecular imaging and targeted radionuclide therapy for the past three decades. He previously worked at Weill Cornell Medical College for several years as a Chief of Radiopharmaceutical Sciences in Radiology, was President & Chief Scientific Officer, Molecular Insight Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of innovative radiopharmaceuticals in the emerging field of molecular medicine, and Assistant Professor of Radiology at Harvard Medical School, and Principal Nuclear Pharmacist at Massachusetts General Hospital. Dr. Babich has a Ph.D. with a focus in Biophysics, Medical Physics and Radiation Biology from University of London, an M.Sc., Radiopharmacy, University of Southern California and a B.Sc., Pharmaceutical Sciences from St. John's University.

Support the show